Company profile: Navitor Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of novel medicines targeting nutrient-sensing proteins, including NV-5138, an orally bioavailable small molecule that directly activates mTORC1 for treatment-resistant depression, and AT-20494, a selective mTORC1 inhibitor for autosomal dominant polycystic kidney disease and potentially other conditions.
Products and services
- AT-20494: Selective mTORC1 activity inhibitor aimed at treating autosomal dominant polycystic kidney disease, with potential application to additional conditions
- Nutrient-Sensing Protein-Targeted Medicines Development: Develops novel medicines designed to target specific nutrient-sensing proteins to treat diseases, using target-specific approaches
- NV-5138: Orally bioavailable small molecule that directly activates nutrient-sensing mTORC1, targeting treatment-resistant depression through direct mTORC1 pathway activation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Navitor Pharmaceuticals
CTI Science
HQ: United States
Website
- Description: Provider of biotechnology research and development focused on improving human and animal health, developing a flagship product for submission for regulatory drug approval. Founded in 2007 by Dr. Boyd E. Haley, based in Lexington, Kentucky, United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CTI Science company profile →
Microvascular Tissues
HQ: United States
Website
- Description: Provider of biological vascular tissues for implantation, including mVASC Microvascular Tissue, a sterile, off-the-shelf human microvascular tissue graft designed to restore blood flow and support natural healing in damaged tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Microvascular Tissues company profile →
Zealand Pharma
HQ: Denmark
Website
- Description: Provider of peptide-based medicines and novel specialty drug candidates, leveraging leading-edge expertise and partnerships. Offerings include dasiglucagon for severe hypoglycemia (with Novo Nordisk), survodutide for obesity and MASH (with Boehringer Ingelheim), dapiglutide, and devices such as the investigational bihormonal iLet bionic pancreas (with Beta Bionics) and a continuous infusion pump for congenital hyperinsulinism (with DEKA Research).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zealand Pharma company profile →
Skyepharma
HQ: United Kingdom
Website
- Description: Provider of specialty drug delivery using oral and inhalation technologies to create enhanced versions of existing pharmaceutical products and products with new chemical entities. Offers Geomatrix modified-release tablets, stick-pack unit-dose packaging, serialization and aggregation, formulation development, and cGMP clinical trial manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Skyepharma company profile →
NeRRe Therapeutics
HQ: United Kingdom
Website
- Description: Provider of biotechnology R&D focused on clinical and pre-clinical neurokinin receptor antagonists, including Orvepitant, a neurokinin-1 receptor antagonist in development for treating chronic cough associated with idiopathic pulmonary fibrosis (IPF). Founded in 2012 and based in Stevenage, United Kingdom.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NeRRe Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Navitor Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Navitor Pharmaceuticals
2.2 - Growth funds investing in similar companies to Navitor Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Navitor Pharmaceuticals
4.2 - Public trading comparable groups for Navitor Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →